Status:
ACTIVE_NOT_RECRUITING
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement. Crizotinib may stop the growth of cancer cells by block...
Detailed Description
PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDAR...
Eligibility Criteria
Inclusion
- Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol
- Patients must have an ALK rearrangement as defined via the MATCH Master Protocol
- Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block)
Exclusion
- Patients must not have non small cell lung cancer or anaplastic large cell lymphoma (ALCL)
- Patients with a history of interstitial lung disease or pneumonitis are excluded
- Patients must not have known hypersensitivity to crizotinib or compounds of similar chemical or biologic composition
- Patients must not have had prior ALK-targeted inhibitors, including crizotinib, ceritinib, alectinib, AP26113, TSR-011, X-396, RXDX-101, CEP-37440, PF-06463922
- Patients must not have had brain metastases unless 1) treated and neurologically stable for at least 2 weeks, or 2) untreated, asymptomatic, and treatment is not indicated. Steroids are permitted if doses are stable (or tapering) for 2 weeks prior to study enrollment
- Patients using drugs or foods that are known potent CYP3A4 inhibitors or inducers will be excluded
Key Trial Info
Start Date :
August 12 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 17 2026
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04439266
Start Date
August 12 2015
End Date
March 17 2026
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, United States, 19103